Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02124421 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HOT: HIPEC in Ovarian Cancer as Initial Treatment

Study acronym: CRS/HIPEC
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv15
  2. Primary completion date: Aug 2023 to Aug 2027v14
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 48 to confirmed 32 · Primary completion date: Apr 2023 to Aug 2023 · Site details revisedv13 Show 3 more changesShow less
    • Enrollment target: estimated 48 to confirmed 32
    • Primary completion date: Apr 2023 to Aug 2023
    • Site details revised
  4. Re-verified, no change to tracked fieldsv12
  5. Primary completion date: Apr 2020 to Apr 2023 Completion date: Apr 2020 to Apr 2028v11 Show 1 more changeShow less
    • Completion date: Apr 2020 to Apr 2028
Show 9 earlier versionsHide 9 earlier versions
  1. Study title shortened, about 6 wordsv10 See this version in full on ClinicalTrials.gov ↗
  2. Secondary endpoints: details revised at 2 of 3 entriesv9
  3. Primary completion date: Apr 2018 to Apr 2020v8
  4. Re-verified, no change to tracked fieldsv7
  5. Primary completion date: Apr 2016 to Apr 2018v6
  6. 2 versions Re-verified since Jun 4, 2015, no change to tracked fieldsv4-v5
  7. Interventions: Carboplatin (Drug), Cytoreductive Surgery (CRS) (Procedure), Hyperthermic intraperitoneal chemotherapy (Procedure), Paclitaxel (Drug)… to Adjuvant Chemotherapy (Drug), Carboplatin (Drug), Cisplatin (Drug), Cytoreductive Surgery (CRS) (Procedure), Hyperthermic intraperitoneal… Study description expanded, about 24 wordsv3 Show 1 more changeShow less
    • Study description expanded, about 24 words

    See this version in full on ClinicalTrials.gov ↗

  8. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Community hospital based phase II (prospective randomized) study to evaluate the toxicity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly diagnosed, otherwise untreated, advanced stage (stage III/IV) epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Trial Details
NCT Number NCT02124421
Lead Sponsor Mercy Medical Center
Conditions Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov